Clinical Pharmacology Program, SAIC-Frederick, National Cancer Institute at Frederick, Bethesda, MD, USA.
Anticancer Res. 2012 Jul;32(7):2391-8.
Biphosphonates have long been the standard of care for antiresorptive treatment of bone metastases from castrate-resistant prostate cancer (mCRPC). Although the indication has historically been mostly palliative, response rates in skeletal-related events (SRE) remain low. Denosumab has been shown to be effective in prolonging time to first SRE in clinical settings, however, critical questions remain on its ability to affect bone metastases in mCRPC. The landscape for research progress in reducing SREs using novel pharmacotherapies is growing rapidly, with several agents in clinical trials. This focused review outlines the most promising investigational drugs for treating bone metastases in mCRPC.
双膦酸盐一直是去势抵抗性前列腺癌（mCRPC）骨转移抗吸收治疗的标准治疗方法。尽管该适应症历史上主要是姑息性的，但骨骼相关事件（SRE）的缓解率仍然较低。地舒单抗已被证明在临床环境中能有效延长首次 SRE 的时间，但关于其在 mCRPC 中影响骨转移的能力仍存在一些关键问题。使用新型药物治疗来减少 SRE 的研究进展迅速，临床试验中有几种药物。本重点综述概述了治疗 mCRPC 骨转移最有前途的研究性药物。
